NAV3 and lung carcinoma: NAV3 expression is attenuated in metastatic colon cancer [86], breast cancer and lung cancer [84] and its knockdown promotes invasive behaviors [84,86], platinum drug resistance [88] and epithelial mesenchymal transition in vitro [86] and enhances metastasis in vivo [84].